December 2022 FDA Recall Drug by Remedyrepack Inc.
D-0098-2023 - Failed Impurities/Degradation specifications

This Class II drug recall was voluntarily initiated by Remedyrepack Inc. on December 20, 2022 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in Product was distributed to one account in PA. and the recall is currently terminated.

Recall Number: D-0098-2023

Reason for Recall
Failed Impurities/Degradation specifications
Initiated
12-20-2022
Reported
01-18-2023
Quantity
132 Cards of 30 = 3960 Tablets

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Product was distributed to one account in PA.
Rifampin Capsules, 300 mg, 30 count blister card, Rx only, Mfg: Lupin Pharma, Baltimore, MD 21202, original NDC 68180-0659-07, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, Repackaged NDC 70518-2404-00.

Batch or Lot Expiration Information

Lot# : J0599794-022322, exp. date 02/28/2023; J0621369-052622, exp. date 06/30/2023